Regenerative Medicine, Neurology, Ophthalmology. Company develops stem cell therapies for degenerative retinal and neurological diseases. Its lead product facilitates retinal pigmented epithelial cell transplantation to treat age related macular degeneration, which is the leading cause of visual impairment over the age of 55. The company is also developing neural cells to treat Parkinson’s disease and multiple sclerosis. It seeks $10 million in funding for clinical studies investigating the use of its product in Parkinson’s disease. Founded: 2005.